Plaunotol suppresses interleukin-8 secretion induced by Helicobacter pylori: Therapeutic effect of plaunotol on H. pylori infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 4, 2000, Pages 374-380

  Takagi, Atsushi ^a   Koga, Yasuhiro ^a   Aiba, Yuji ^a   Kabir, Abu M A ^a   Watanabe, Sumio ^a   Ohta Tada, Uki ^a   Osaki, Takako ^b   Kamiya, Shigeru ^b   Miwa, Takeshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adhesion; Gastric cancer cell line; Gnotobiotic murine model; Helicobacter pylori; Interleukin 8

Indexed keywords

INTERLEUKIN 8; PLAUNOTOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ADHERENCE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRITIS; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; MUCOSA CELL; NONHUMAN; PRIORITY JOURNAL; STOMACH MUCOSA INJURY;

EID: 0034062208     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02168.x     Document Type: Article

References (37)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; i: 1311-15.
2. Blaser MJ. Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102: 720-7.
3. Dixon MF. Helicobacter pylori and peptic ulceration: Histopathological aspects. J. Gastroenterol. Hepatol. 1991; 6: 125-30.
4. Marshall BJ, Goodwin CS, Warren JR et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; ii: 1437-42.
5. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233-5.
6. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am. J. Gastroenterol. 1992; 87: 1716-27.
7. Hazell SL, Lee A, Brady L, Hennessy W. Campylobacter pyloridis and gastritis: association with intercellular space and adaption to an environment of mucus as important factors in colonization of the gastric epithelium. J. Infect. Dis. 1986; 153: 658-63.
8. Wyatt JI, Rathbone BJ, Sobala GM et al. Gastric epithelium in the duodenum: its association with Helicobacter pylori and inflammation. J. Clin. Pathol. 1990; 43: 981-6.
9. Clyne M, Drumm B. Adherence of Helicobacter pylori to primary human gastrointestinal cells. Infect. Immun. 1993; 61: 4051-7.
10. Yamamoto-Osaki T, Yamaguchi H, Taguchi H, Ogata S, Kamiya S. Adherence of Helicobacter pylori to cultured human gastric carcinoma cells. Eur. J. Gastroenterol. Hepatol. 1995; 7: S89-92.
11. Kobayashi S, Yamazaki M, Komai T, Miyoshi A. CS-684 (plaunotol) a new antiulcer agent: Pharmacology and clinical evaluation. In: Miyoshi A, ed. New Trends in Peptic Ulcer and Chronic Gastritis. Tokyo: Excerpta Medica 1987; 377-83.
12. Koga T, Kawada H, Utsui Y, Domon H, Ishii C, Yasuda H. In vitro and in vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori. J. Antimicrob. Chemother. 1996; 37: 919-29.
13. Gionchetti P, Varia D, Campieri M et al. Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am. J. Gastroenterol. 1994; 89: 883-7.
14. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJH, Tytgat GNG. Mucosal tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 production in patients with Helicobaaer pylori infection. Scand. J. Gastroenterol. 1994; 29: 425-9.
15. Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32: 1473-7.
16. Crabtree JE, Peichl P, Wyatt JI, Stachl U, Linddley IJD. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand. J. Immunol. 1993; 37: 65-70.
17. Suzuki M, Miura S, Suematsu M et al. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. Am. J. Physiol. 1992; 263: G719-25.
18. Murakami M, Asagoe K, Dekigai H, Kusaka S, Saita H, Kita T. Products of neutrophil metabolism increase ammonia-induced gastric mucosal damage. Dig. Dis. Sci. 1995; 40: 268-73.
19. Crabtree JE. The role of cytokines in Helicobacter pylori infection. Mucosal Immunol. Update 1994; 2: 5-7.
20. Kamiya S, Kai M, Ozawa A et al. Characteristics of vacuolating toxin produced by Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 1994; 6 (Suppl. 1): S23-7.
21. Tummura MKR, Cover TL, Blaser MJ. Cloning and expression of a high-molecular mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect. Immun. 1993; 61: 1799-809.
22. Takagi A, Kamiya S, Koga Y et al. Analysis of interleukin-8 secretion induced by Helicobaaer pylori from the gastric epithelial cell line MKN45: a mechanism independent of intensity of cytotoxicity. J. Gastroenterol. Hepatol. 1997; 12: 368-72.
23. Kabir AMA, Aiba Y, Takagi A, Kamiya S, Miwa T, Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997; 41: 49-55.
24. Mohammadi M, Czinn S, Redline R, Nedrud J. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J. Immunol. 1996; 156: 4729-38.
25. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
26. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobaaer pylori. Gastroenterology 1992; 102: 493-6.
27. Megraud F. H. pylori resistances to antibiotics. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht: Kluwer Academic Publishers, 1994; 570-83.
28. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 639-42.
29. Ushiyama S, Matsuda K, Asai F, Yamazaki M. Stimulation of prostaglandin production by (2E, 6Z, 10E) -7-hydroxy-methyl-3,11,15-trimethyl-2,6,10,14-hexadecatetraen-1-ol (plaunotol), a new anti-ulcer drug, in vitro and in vivo. Biochem. Pharmacol. 1987; 36: 369-75.
30. Kaneko H, Mitsuma T, Nagai H et al. Effect of plaunotol on hypergastrinemia induced by long-term omeprazole administration in humans. Dig. Dis. Sci. 1995; 40: 160-5.
31. Shirai T, Takagi A, Kurumada T et al. Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients. J. Clin. Gastroenterol. 1995; 20: S128-31.
32. Eckmann L, Kagnoff MF, Fierer J. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect. Immun. 1993; 61: 4569-74.
33. Crabtree JE, Farmery SM, Lindley IJD, Figura N, Peichl P, Tompkins DS. CagA/cytotoxic strain of H. pylori and interleukin-8 in gastric epithelial cell lines. J. Clin. Pathol. 1994; 47: 945-50.
34. Crowe SE, Alvarez L, Dytoc M et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 1995; 108: 65-74.
35. Sharma SA, Tummuru MKR, Miller GG, Blaser MJ. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect. Immun. 1995; 63: 1681-7.
36. Huang J, O'Toole PW, Doig P, Trust TJ. Stimulation of interleukin-8 production in epithelial cell lines by Helicobacter pylori. Infect. Immun. 1995; 63: 1732-8.
37. Karita M, Quin L, Okita K. Evaluation of new therapy for eradication of H. pylori infection in nude mouse model. Am. J. Gastroenterol. 1993; 88: 1366-72.